Zobrazeno 1 - 10
of 2 212
pro vyhledávání: '"anti-cd20 monoclonal antibody"'
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 3025-3042 (2024)
Sarah-Jane Martin,1,2 Melanie Guenette,1 Jiwon Oh1 1Division of Neurology, Department of Medicine, St Michael’s Hospital, Toronto, Canada; 2University of Glasgow, Glasgow, UKCorrespondence: Jiwon Oh, Email jiwon.oh@unityhealth.toAbstract: B cells a
Externí odkaz:
https://doaj.org/article/b4c07be9cd14429ba1894b22c11ed442
Autor:
Yuankai Shi, Keshu Zhou, Hui Zhou, Yan Qin, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang, Yongping Song, Jinjin Liang, Min Wei
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102702- (2024)
Summary: Background: MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, with a nearly completely afucosylated N-glycans in Fc region, has demonstrated superior activity compared with rituximab and obinutuzumab in vitro and in vivo
Externí odkaz:
https://doaj.org/article/2a3c6df3d77e4c00af3f193cded6e60d
Autor:
Zhi-hui Tu, Ding-ping Yang
Publikováno v:
Linchuang shenzangbing zazhi, Vol 24, Iss 2, Pp 89-95 (2024)
ObjectiveTo compare the clinical efficacy and safety of two regimens of rituximab (RTX) for idiopathic membranous nephropathy (IMN).MethodsA total of 79 IMN patients were recruited from December 01, 2019 to December 31, 2021. RTX two-dose regimen gro
Externí odkaz:
https://doaj.org/article/678f8be630fe491aa31ea9b016844e81
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 157-161 (2024)
Abstract Thrombocytopenia has been reported more frequently with obinutuzumab in clinical trials where it was directly compared with rituximab. However, more significant than the frequency, a unique form of severe thrombocytopenia manifesting very ea
Externí odkaz:
https://doaj.org/article/cc11b12b0ca848ffbba6b4296c88fcb0
Autor:
Stephen L. Hauser, Ludwig Kappos, Amit Bar-Or, Heinz Wiendl, David Paling, Mitzi Williams, Ralf Gold, Andrew Chan, Ron Milo, Ayan Das Gupta, Goeril Karlsson, Roseanne Sullivan, Gordon Graham, Martin Merschhemke, Dieter A. Häring, Patrick Vermersch
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1491-1515 (2023)
Abstract The importance of B cells in multiple sclerosis (MS) has been demonstrated through the advent of B-cell-depleting anti-CD20 antibody therapies. Ofatumumab is the first fully human anti-CD20 monoclonal antibody (mAb) developed and tested for
Externí odkaz:
https://doaj.org/article/eebd67c7598744dda6a94266f7a71dd5
Publikováno v:
Thrombosis Journal, Vol 21, Iss 1, Pp 1-4 (2023)
Abstract Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder secondary to development of antibodies against prothrombin protein, in the presence of antiphospholipid antibodies. We describe the case of a 13-ye
Externí odkaz:
https://doaj.org/article/6be3bb82c2834184917c17c801f91ef3
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 883-890 (2023)
Yanisa Ratanapokasatit, Chutima Seree-Aphinan, Kumutnart Chanprapaph Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Kumutnart Chanprapaph, Division of D
Externí odkaz:
https://doaj.org/article/54e2779e5e25461eb4423074f928c56e
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 1745-1759 (2023)
Marginal zone lymphomas (MZL) are a rare, heterogenous group of lymphomas, accounting for 5–17% of indolent non-Hodgkin lymphomas in the western world. They can be further divided into three subtypes: extranodal MZL, splenic MZL, and nodal MZL. The
Externí odkaz:
https://doaj.org/article/fe5aad47d91e40fb88f27f264e4ae5d9
Autor:
Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J
Publikováno v:
Infection and Drug Resistance, Vol Volume 16, Pp 509-519 (2023)
Akio Onishi,1 Yayoi Matsumura-Kimoto,1,2 Shinsuke Mizutani,1 Taku Tsukamoto,1 Takahiro Fujino,1 Akihiro Miyashita,1,3 Daichi Nishiyama,4 Kazuho Shimura,5 Hiroto Kaneko,5 Eri Kawata,6 Ryoichi Takahashi,7 Tsutomu Kobayashi,1,8 Hitoji Uchiyama,8 Nobuhik
Externí odkaz:
https://doaj.org/article/78f3221619794f469499ce032a0b7b49
Publikováno v:
Journal of Genetic Engineering and Biotechnology, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background Recombinant therapeutic anti-CD20 monoclonal antibody (mAb) is used for the treatment of non-Hodgkin’s lymphoma, a common B cell lymphoma constituting 80% of all lymphomas. Anti-CD20 mAb contains an Fc-linked biantennary glycan.
Externí odkaz:
https://doaj.org/article/a722f381dc014b94b08bd9cc195ca486